Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical have teamed up to study the most common type of metastatic colorectal cancer (mCRC).

The three companies will collaborate to test Bayer’s kinase inhibitor Stivarga (regorafenib) and Bristol-Myers Squibb’s and Ono’s anti-PD-1 checkpoint inhibitor Opdivo (nivolumab) in microsatellite stable metastatic colorectal cancer (MSS mCRC).